<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39339845</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>28</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Type I Interferonopathy among Non-Elderly Female Patients with Post-Acute Sequelae of COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1369</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091369</ELocationID><Abstract><AbstractText>The pathophysiological mechanisms of the post-acute sequelae of COVID-19 (PASC) remain unclear. Sex differences not only exist in the disease severity of acute SARS-CoV-2 infection but also in the risk of suffering from PASC. Women have a higher risk of suffering from PASC and a longer time to resolution than men. To explore the possible immune mechanisms of PASC among non-elderly females, we mined single-cell transcriptome data from peripheral blood samples of non-elderly female patients with PASC and acute SARS-CoV-2 infection, together with age- and gender-matched non-PASC and healthy controls available from the Gene Expression Omnibus database. By comparing the differences, we found that a CD14<sup>+</sup> monocyte subset characterized by higher expression of signal transducers and activators of transcription 2 (STAT2) (CD14<sup>+</sup>STAT2<sup>high</sup>) was notably increased in the PASC patients compared with the non-PASC individuals. The transcriptional factor (TF) activity analysis revealed that STAT2 and IRF9 were the key TFs determining the function of CD14<sup>+</sup>STAT2<sup>high</sup> monocytes. STAT2 and IRF9 are TFs exclusively involving type I and III interferon (IFN) signaling pathways, resulting in uncontrolled IFN-I signaling activation and type I interferonopathy. Furthermore, increased expression of common interferon-stimulated genes (ISGs) has also been identified in most monocyte subsets among the non-elderly female PASC patients, including IFI6, IFITM3, IFI44L, IFI44, EPSTI1, ISG15, and MX1. This study reveals a featured CD14<sup>+</sup>STAT2<sup>high</sup> monocyte associated with uncontrolled IFN-I signaling activation, which is indicative of a possible type I interferonopathy in the non-elderly female patients with PASC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Donghua</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Comparative Pathology, Tulane National Primate Research Center, Tulane University School of Medicine, Tulane University, 18703 Three Rivers Road, Covington, LA 70433, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, Tulane University, New Orleans, LA 70112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Xuebin</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-9875-983X</Identifier><AffiliationInfo><Affiliation>Division of Comparative Pathology, Tulane National Primate Research Center, Tulane University School of Medicine, Tulane University, 18703 Three Rivers Road, Covington, LA 70433, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, Tulane University, New Orleans, LA 70112, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01DK129881</GrantID><Agency>X.Q.</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050795">STAT2 Transcription Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018950">Lipopolysaccharide Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494084">STAT2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494227">IRF9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000632510">CD14 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050835">Interferon Regulatory Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050834">Interferon-Stimulated Gene Factor 3, gamma Subunit</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="Y">Monocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050795" MajorTopicYN="N">STAT2 Transcription Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018950" MajorTopicYN="N">Lipopolysaccharide Receptors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050835" MajorTopicYN="N">Interferon Regulatory Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050834" MajorTopicYN="N">Interferon-Stimulated Gene Factor 3, gamma Subunit</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">females</Keyword><Keyword MajorTopicYN="N">non-elderly</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of COVID-19</Keyword><Keyword MajorTopicYN="N">signal transducers and activators of transcription 2</Keyword><Keyword MajorTopicYN="N">type I interferon signaling</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339845</ArticleId><ArticleId IdType="pmc">PMC11435747</ArticleId><ArticleId IdType="doi">10.3390/v16091369</ArticleId><ArticleId IdType="pii">v16091369</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Aly Z., Topol E. Solving the puzzle of Long COVID. Science. 2024;383:830–832. doi: 10.1126/science.adl0867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adl0867</ArticleId><ArticleId IdType="pubmed">38386747</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Abdel-Mohsen M., Henrich T.J., Roan N.R. Seminars in Immunology. Volume 72. Academic Press; Cambridge, MA, USA: 2024. Systems analysis of innate and adaptive immunity in Long COVID; p. 101873.</Citation><ArticleIdList><ArticleId IdType="pubmed">38460395</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Wood J., Jaycox J.R., Dhodapkar R.M., Lu P., Gehlhausen J.R., Tabachnikova A., Greene K., Tabacof L., Malik A.A., et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623:139–148. doi: 10.1038/s41586-023-06651-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Sawano M., Wu Y., Shah R.M., Bishop P., Iwasaki A., Krumholz H.M. Factors Associated with Long COVID: Insights from Two Nationwide Surveys. Am. J. Med. 2024;137:515–519. doi: 10.1016/j.amjmed.2024.02.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2024.02.032</ArticleId><ArticleId IdType="pubmed">38490304</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626–631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., Myles P., Williams T., Gokhale K.M., Taverner T., Chandan J.S., Brown K., Simms-Williams N., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022;28:1706–1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S.M., Premraj L., Battaglini D., Fanning J.P., Suen J., Bassi G.L., Fraser J., Robba C., Griffee M., Solomon T., et al. Sex differences in post-acute neurological sequelae of SARS-CoV-2 and symptom resolution in adults after coronavirus disease 2019 hospitalization: An international multi-centre prospective observational study. Brain Commun. 2024;6:fcae036. doi: 10.1093/braincomms/fcae036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcae036</ArticleId><ArticleId IdType="pmc">PMC10914448</ArticleId><ArticleId IdType="pubmed">38444907</ArticleId></ArticleIdList></Reference><Reference><Citation>Giroux N.S., Ding S., McClain M.T., Burke T.W., Petzold E., Chung H.A., Rivera G.O., Wang E., Xi R., Bose S., et al. Differential chromatin accessibility in peripheral blood mononuclear cells underlies COVID-19 disease severity prior to seroconversion. Sci. Rep. 2022;12:11714. doi: 10.1038/s41598-022-15668-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-15668-8</ArticleId><ArticleId IdType="pmc">PMC9271053</ArticleId><ArticleId IdType="pubmed">35810186</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.S., Park S., Jeong H.W., Ahn J.Y., Choi S.J., Lee H., Choi B., Nam S.K., Sa M., Kwon J.S., et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci. Immunol. 2020;5:eabd1554. doi: 10.1126/sciimmunol.abd1554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd1554</ArticleId><ArticleId IdType="pmc">PMC7402635</ArticleId><ArticleId IdType="pubmed">32651212</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin K., Peluso M.J., Luo X., Thomas R., Shin M.G., Neidleman J., Andrew A., Young K.C., Ma T., Hoh R., et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat. Immunol. 2024;25:218–225. doi: 10.1038/s41590-023-01724-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01724-6</ArticleId><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Bai H., Ma J., Qin H., Zeng Q., Hu F., Jiang T., Mao W., Zhao Y., Chen X., et al. Identification of Distinct Immune Cell Subsets Associated with Asymptomatic Infection, Disease Severity, and Viral Persistence in COVID-19 Patients. Front. Immunol. 2022;13:812514. doi: 10.3389/fimmu.2022.812514.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.812514</ArticleId><ArticleId IdType="pmc">PMC8905648</ArticleId><ArticleId IdType="pubmed">35281000</ArticleId></ArticleIdList></Reference><Reference><Citation>Unterman A., Sumida T.S., Nouri N., Yan X., Zhao A.Y., Gasque V., Schupp J.C., Asashima H., Liu Y., Cosme C., et al. Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. Nat. Commun. 2022;13:440. doi: 10.1038/s41467-021-27716-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27716-4</ArticleId><ArticleId IdType="pmc">PMC8782894</ArticleId><ArticleId IdType="pubmed">35064122</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon H., Dean L.S., Jiyarom B., Khadka V.S., Deng Y., Nerurkar V.R., Chow D.C., Shikuma C.M., Devendra G., Koh Y., et al. Single-cell RNA sequencing reveals characteristics of myeloid cells in post-acute sequelae of SARS-CoV-2 patients with persistent respiratory symptoms. Front. Immunol. 2023;14:1268510. doi: 10.3389/fimmu.2023.1268510.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1268510</ArticleId><ArticleId IdType="pmc">PMC10800799</ArticleId><ArticleId IdType="pubmed">38259488</ArticleId></ArticleIdList></Reference><Reference><Citation>Terzoli S., Marzano P., Cazzetta V., Piazza R., Sandrock I., Ravens S., Tan L., Prinz I., Balin S., Calvi M., et al. Expansion of memory Vdelta2 T cells following SARS-CoV-2 vaccination revealed by temporal single-cell transcriptomics. NPJ Vaccines. 2024;9:63. doi: 10.1038/s41541-024-00853-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-024-00853-9</ArticleId><ArticleId IdType="pmc">PMC10954735</ArticleId><ArticleId IdType="pubmed">38509155</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna B.A., Lim E.Y., Metaxaki M., Jackson S., Mactavous L., BioResource N., Lyons P.A., Doffinger R., Bradley J.R., Smith K.G.C., et al. Spontaneous, persistent, T cell-dependent IFN-gamma release in patients who progress to Long COVID. Sci. Adv. 2024;10:eadi9379. doi: 10.1126/sciadv.adi9379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.adi9379</ArticleId><ArticleId IdType="pmc">PMC10881041</ArticleId><ArticleId IdType="pubmed">38381822</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskandarian Boroujeni M., Sekrecka A., Antonczyk A., Hassani S., Sekrecki M., Nowicka H., Lopacinska N., Olya A., Kluzek K., Wesoly J., et al. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy. Front. Immunol. 2022;13:888897. doi: 10.3389/fimmu.2022.888897.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.888897</ArticleId><ArticleId IdType="pmc">PMC9156796</ArticleId><ArticleId IdType="pubmed">35663932</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaszczyk K., Nowicka H., Kostyrko K., Antonczyk A., Wesoly J., Bluyssen H.A. The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine Growth Factor Rev. 2016;29:71–81. doi: 10.1016/j.cytogfr.2016.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2016.02.010</ArticleId><ArticleId IdType="pubmed">27053489</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowicka H., Sekrecka A., Blaszczyk K., Kluzek K., Chang C.Y., Wesoly J., Lee C.K., Bluyssen H.A.R. ISGF3 and STAT2/IRF9 Control Basal and IFN-Induced Transcription through Genome-Wide Binding of Phosphorylated and Unphosphorylated Complexes to Common ISRE-Containing ISGs. Int. J. Mol. Sci. 2023;24:17635. doi: 10.3390/ijms242417635.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242417635</ArticleId><ArticleId IdType="pmc">PMC10743977</ArticleId><ArticleId IdType="pubmed">38139463</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu G., Badonyi M., Franklin L., Seabra L., Rice G.I., Anne Boland A., Deleuze J.F., El-Chehadeh S., Anheim M., de Saint-Martin A., et al. Type I Interferonopathy due to a Homozygous Loss-of-Inhibitory Function Mutation in STAT2. J. Clin. Immunol. 2023;43:808–818. doi: 10.1007/s10875-023-01445-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-023-01445-3</ArticleId><ArticleId IdType="pmc">PMC10110676</ArticleId><ArticleId IdType="pubmed">36753016</ArticleId></ArticleIdList></Reference><Reference><Citation>Park C., Li S., Cha E., Schindler C. Immune response in Stat2 knockout mice. Immunity. 2000;13:795–804. doi: 10.1016/S1074-7613(00)00077-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(00)00077-7</ArticleId><ArticleId IdType="pubmed">11163195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciol G., Moens L., Ogishi M., Rinchai D., Matuozzo D., Momenilandi M., Kerrouche N., Cale C.M., Treffeisen E.R., Al Salamah M., et al. Human inherited complete STAT2 deficiency underlies inflammatory viral diseases. J. Clin. Investig. 2023;133:e168321. doi: 10.1172/JCI168321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI168321</ArticleId><ArticleId IdType="pmc">PMC10266780</ArticleId><ArticleId IdType="pubmed">36976641</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan C.J.A., Thompson B.J., Chen R., Rice G.I., Gothe F., Young D.F., Lovell S.C., Shuttleworth V.G., Brocklebank V., Corner B., et al. Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2. Sci. Immunol. 2019;4:eaav7501. doi: 10.1126/sciimmunol.aav7501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aav7501</ArticleId><ArticleId IdType="pmc">PMC7115903</ArticleId><ArticleId IdType="pubmed">31836668</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudewijns R., Thibaut H.J., Kaptein S.J.F., Li R., Vergote V., Seldeslachts L., Van Weyenbergh J., De Keyzer C., Bervoets L., Sharma S., et al. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nat. Commun. 2020;11:5838. doi: 10.1038/s41467-020-19684-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19684-y</ArticleId><ArticleId IdType="pmc">PMC7672082</ArticleId><ArticleId IdType="pubmed">33203860</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew F., Efstathiou C., Fontanella S., Richardson M., Saunders R., Swieboda D., Sidhu J.K., Ascough S., Moore S.C., Mohamed N., et al. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nat. Immunol. 2024;25:607–621. doi: 10.1038/s41590-024-01778-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-024-01778-0</ArticleId><ArticleId IdType="pmc">PMC11003868</ArticleId><ArticleId IdType="pubmed">38589621</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz M.A.F., Brito W., Pereira K.A.S., Pereira L.M.S., Amoras E., Lima S.S., Santos E.F.D., Costa F.P.D., Sarges K.M.L., Cantanhede M.H.D., et al. Severe COVID-19 and long COVID are associated with high expression of STING, cGAS and IFN-alpha. Sci. Rep. 2024;14:4974. doi: 10.1038/s41598-024-55696-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-55696-0</ArticleId><ArticleId IdType="pmc">PMC10904751</ArticleId><ArticleId IdType="pubmed">38424312</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallucci S., Meka S., Gamero A.M. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity. Cytokine. 2021;146:155633. doi: 10.1016/j.cyto.2021.155633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2021.155633</ArticleId><ArticleId IdType="pmc">PMC8475157</ArticleId><ArticleId IdType="pubmed">34340046</ArticleId></ArticleIdList></Reference><Reference><Citation>Guery J.C. Sex Differences in Primary HIV Infection: Revisiting the Role of TLR7-Driven Type 1 IFN Production by Plasmacytoid Dendritic Cells in Women. Front. Immunol. 2021;12:729233. doi: 10.3389/fimmu.2021.729233.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.729233</ArticleId><ArticleId IdType="pmc">PMC8432934</ArticleId><ArticleId IdType="pubmed">34512664</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiering A.E., de Vries T.J. Why Females Do Better: The X Chromosomal TLR7 Gene-Dose Effect in COVID-19. Front. Immunol. 2021;12:756262. doi: 10.3389/fimmu.2021.756262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.756262</ArticleId><ArticleId IdType="pmc">PMC8632002</ArticleId><ArticleId IdType="pubmed">34858409</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanana N., Palmo T., Sharma K., Kumar R., Graham B.B., Pasha Q. Sex-derived attributes contributing to SARS-CoV-2 mortality. Am. J. Physiol. Endocrinol. Metab. 2020;319:E562–E567. doi: 10.1152/ajpendo.00295.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00295.2020</ArticleId><ArticleId IdType="pmc">PMC7473885</ArticleId><ArticleId IdType="pubmed">32726128</ArticleId></ArticleIdList></Reference><Reference><Citation>Umiker B.R., Andersson S., Fernandez L., Korgaokar P., Larbi A., Pilichowska M., Weinkauf C.C., Wortis H.H., Kearney J.F., Imanishi-Kari T. Dosage of X-linked Toll-like receptor 8 determines gender differences in the development of systemic lupus erythematosus. Eur. J. Immunol. 2014;44:1503–1516. doi: 10.1002/eji.201344283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201344283</ArticleId><ArticleId IdType="pmc">PMC4028042</ArticleId><ArticleId IdType="pubmed">24500834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagen S.H., Henseling F., Hennesen J., Savel H., Delahaye S., Richert L., Ziegler S.M., Altfeld M. Heterogeneous Escape from X Chromosome Inactivation Results in Sex Differences in Type I IFN Responses at the Single Human pDC Level. Cell Rep. 2020;33:108485. doi: 10.1016/j.celrep.2020.108485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108485</ArticleId><ArticleId IdType="pmc">PMC7833293</ArticleId><ArticleId IdType="pubmed">33296655</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Carballa A., Pardo-Seco J., Pischedda S., Rivero-Calle I., Butler-Laporte G., Richards J.B., Viz-Lasheras S., Martinon-Torres F., Salas A., Network G. Sex-biased expression of the TLR7 gene in severe COVID-19 patients: Insights from transcriptomics and epigenomics. Pt 2Env. Res. 2022;215:114288. doi: 10.1016/j.envres.2022.114288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2022.114288</ArticleId><ArticleId IdType="pmc">PMC9508271</ArticleId><ArticleId IdType="pubmed">36152884</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallerini C., Daga S., Mantovani S., Benetti E., Picchiotti N., Francisci D., Paciosi F., Schiaroli E., Baldassarri M., Fava F., et al. Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study. Elife. 2021;10:e67569. doi: 10.7554/eLife.67569.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.67569</ArticleId><ArticleId IdType="pmc">PMC7987337</ArticleId><ArticleId IdType="pubmed">33650967</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano T., Boisson B., Onodi F., Matuozzo D., Moncada-Velez M., Maglorius Renkilaraj M.R.L., Zhang P., Meertens L., Bolze A., Materna M., et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci. Immunol. 2021;6:62. doi: 10.1126/sciimmunol.abl4348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4348</ArticleId><ArticleId IdType="pmc">PMC8532080</ArticleId><ArticleId IdType="pubmed">34413140</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng F., Dai C., Cai P., Wang J., Xu L., Li J., Hu G., Wang Z., Zheng F., Wang L. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex. J. Med. Virol. 2020;92:2050–2054. doi: 10.1002/jmv.25989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25989</ArticleId><ArticleId IdType="pmc">PMC7267228</ArticleId><ArticleId IdType="pubmed">32383183</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusev E., Sarapultsev A. Exploring the Pathophysiology of Long COVID: The Central Role of Low-Grade Inflammation and Multisystem Involvement. Int. J. Mol. Sci. 2024;25:6389. doi: 10.3390/ijms25126389.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25126389</ArticleId><ArticleId IdType="pmc">PMC11204317</ArticleId><ArticleId IdType="pubmed">38928096</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi A., Whitehead C., Surrao K., Pillai A., Madeshiya A., Li Y., Khodadadi H., Ahmed A.O., Turecki G., Baban B., et al. Type 1 interferon mediates chronic stress-induced neuroinflammation and behavioral deficits via complement component 3-dependent pathway. Mol. Psychiatry. 2021;26:3043–3059. doi: 10.1038/s41380-021-01065-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01065-6</ArticleId><ArticleId IdType="pmc">PMC8497654</ArticleId><ArticleId IdType="pubmed">33833372</ArticleId></ArticleIdList></Reference><Reference><Citation>Jodele S., Medvedovic M., Luebbering N., Chen J., Dandoy C.E., Laskin B.L., Davies S.M. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv. 2020;4:1166–1177. doi: 10.1182/bloodadvances.2020001515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020001515</ArticleId><ArticleId IdType="pmc">PMC7094010</ArticleId><ArticleId IdType="pubmed">32208488</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Connors J.M., Levy J.H. Seminars in Thrombosis and Hemostasis. Volume 50. Thieme Medical Publishers; New York, NY, USA: 2024. What Role Does Microthrombosis Play in Long COVID? pp. 527–536.</Citation><ArticleIdList><ArticleId IdType="pubmed">37748518</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>